ConductScience.org, home

Trial · NCT07912151

Dynamic Stabilometry Combined With Transcranial Direct Current Stimulation for Balance and Motor Recovery After Ischemic Stroke

NCT07912151, Not applicable, Not yet recruiting, Samara State Medical University

3 sourcestrials-2026-11-12-0.4.0

Download JSON
Cite this record

ConductScience Library. Dynamic Stabilometry Combined With Transcranial Direct Current Stimulation for Balance and Motor Recovery After Ischemic Stroke. Trials, record NCT07912151. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07912151

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
Dynamic Stabilometry Combined With Transcranial Direct Current Stimulation for Balance and Motor Recovery After Ischemic Stroke
NCT number
NCT07912151
Status
Not yet recruiting
Phases
Not applicable
Enrollment
120 participants, estimated
Lead sponsor
Samara State Medical University
Conditions
Hemiparesis, Ischemic Stroke, Stroke Rehabilitation, Postural Balance
Interventions
Dynamic Stabilometry With Biofeedback, Static Stabilometry, Anodal tDCS, Sham tDCS, Standard Rehabilitation
First posted
2026-11-03
Last updated
2026-11-03

Source ClinicalTrials.gov

Registered outcomes11

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryChange from Baseline in Berg Balance Scale (BBS)Baseline (Day 0) and Day 12The BBS assesses static and dynamic balance with 14 items; total score ranges from 0 to 56, where higher scores indicate better balance.
SecondaryChange from Baseline in Berg Balance Scale (BBS) at Day 6Baseline (Day 0) and Day 6Interim BBS assessment; range 0 to 56, where higher scores indicate better balance.
SecondaryChange from Baseline in Functional Independence Measure (FIM)Day 0, Day 6, Day 12The FIM assesses the level of assistance needed in daily activities (motor and cognitive domains); total score ranges from 18 to 126, where higher scores indicate greater independence.
SecondaryChange from Baseline in Morse Fall Scale (MFS)Day 0, Day 6, Day 12The MFS estimates fall risk from six items; score ranges from 0 to 125, where higher scores indicate higher fall risk.
SecondaryChange from Baseline in Hauser Ambulation Index (HAI)Day 0, Day 6, Day 12The HAI rates walking ability from 0 (fully active) to 9 (restricted to wheelchair, unable to transfer), where higher scores indicate worse mobility.
SecondaryChange from Baseline in modified Rankin Scale (mRS)Day 0, Day 6, Day 12The mRS measures global disability and dependence; range 0 (no symptoms) to 6 (death), where higher scores indicate greater disability.
SecondaryChange from Baseline in Rivermead Mobility Index (RMI)Day 0, Day 6, Day 12The RMI assesses functional mobility with 15 items from turning in bed to running; range 0 to 15, where higher scores indicate better mobility.
SecondaryChange from Baseline in National Institutes of Health Stroke Scale (NIHSS)Day 0, Day 6, Day 12The NIHSS quantifies stroke-related neurological deficit; range 0 to 42, where higher scores indicate more severe deficit.
SecondaryChange from Baseline in Medical Research Council (MRC) Muscle Strength ScoreDay 0, Day 6, Day 12Muscle strength of the paretic limbs graded per muscle group from 0 (no contraction) to 5 (normal strength), where higher scores indicate greater strength.
SecondaryChange from Baseline in Modified Ashworth Scale (MAS)Day 0, Day 6, Day 12The MAS measures resistance to passive movement (spasticity) from 0 to 4, where higher scores indicate more severe spasticity.

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Source

Release
trials-2026-11-12-0.4.0
Release manifest SHA-256
0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
Registry capture
2026-11-12
Results copy, AACT
2026-03-23
NIH clinical studies file
2026-11-13

Source ClinicalTrials.gov

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07912151

GET https://conductscience.org/api/trials/v1/NCT07912151/registered